“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in
Last close As at 17/03/2023
—
— 0.00 (0.00%)
Market capitalisation
35m
Research: Industrials
FY18 results met revenue and company-defined adjusted EBITDA guidance, although accounting changes and impairments led to higher depreciation charges than we expected. As a result, the adjusted pre-tax loss was a little below our estimate. The Suriname offshore base management contract is a prime driver of significant improvement in FY19, with group revenues set to almost double. However, even in other territories underlying progress is occurring, notably in Egypt, Cyprus and Malta, with potential for significant new opportunities to land this year for both the ILSS and OCTG operations. These may have helped to progress the major shareholders’ intentions to sell to a strategic partner.
Medserv |
A platform for growth |
FY19 forecast release |
Industrial support services |
23 May 2019 |
Share price performance
Business description
Next events
Analyst
Medserv is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||
FY18 results met revenue and company-defined adjusted EBITDA guidance, although accounting changes and impairments led to higher depreciation charges than we expected. As a result, the adjusted pre-tax loss was a little below our estimate. The Suriname offshore base management contract is a prime driver of significant improvement in FY19, with group revenues set to almost double. However, even in other territories underlying progress is occurring, notably in Egypt, Cyprus and Malta, with potential for significant new opportunities to land this year for both the ILSS and OCTG operations. These may have helped to progress the major shareholders’ intentions to sell to a strategic partner.
Year end |
Revenue (€m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/17 |
28.8 |
(3.6) |
(5.6) |
0.0 |
N/A |
N/A |
12/18 |
36.2 |
(3.4) |
(6.8) |
0.0 |
N/A |
N/A |
12/19e |
63.1 |
2.4 |
5.2 |
0.0 |
21.3 |
N/A |
12/20e |
57.2 |
4.2 |
8.9 |
2.0 |
12.5 |
1.8 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
FY18 results: A year of transition
We would regard 2018 as a year of transition for Medserv. New operations in Egypt commenced, Cyprus oil discoveries transformed prospects for the base, Oman OCTG ( oil country tubular goods) operations were transferred to the new facility at Duqm and the Suriname base management contract for ILSS (integrated logistic support services – offshore support bases) not only extended operations beyond the EMEA region, but also introduced management services as a new and sizeable revenue stream. FY18 results met management revenue and EBITDA expectations, providing the foundation for growth, despite some deferrals of OCTG prospects.
Strong EBITDA development expected
Management’s FY19 forecasts expect sales to double due to the large Suriname contract, also delivering strong EBITDA growth. Even if this contract ends after its 15-month term, workload elsewhere is expected to deliver EBITDA growth in FY20 and beyond. Our forecasts do not include identified projects that management is indicating for both OCTG (in the Middle East and Uganda) and ILSS (primarily Middle East), which offer potential upside to our FY20 forecast. As usual there are also some in-year engineering contracts that could bolster FY19 performance if awarded. Overall Medserv is now truly expanding internationally and appears to be increasingly verifying its credentials.
Valuation: Moving into a profitable growth phase
Our revised estimates indicate positive EPS delivery from 2019, with growing contributions expected as Medserv progressively expands its operations internationally. An FY20e P/E ratio of 12.5x appears undemanding. Our capped DCF indicates a value of €1.33 per share at present, but we see upside to this if significant new long-term contracts are awarded this year.
FY18 results
Medserv published FY18 results, which beat management EBITDA expectations modestly on revenues that were pretty much as expected. The key highlights were:
■
Revenues of €36.2m (FY17: €28.8m) were up 26% and marginally better than both management guidance and our own expectations.
■
Company adjusted EBITDA expanded 69% to €7.3m (FY17: €4.3m), again modestly ahead of guidance.
■
Edison adjusted EBITDA of €6.3m (FY17: €3.7m), which excludes other operating income, was up 71%, but 3% below our estimate, offset in the company defined EBITDA by the other operating income, which was higher than we anticipated.
■
Reported EBIT loss of €3.5m (FY17: €4.1m) was lower than the prior year despite a net asset impairment charge relating to OCTG assets in Iraq and Sohar, Oman.
■
Net debt at the year-end had expanded modestly to €53.7m (FY17: €49.2m).
■
No dividend has been declared as a result of the continuing net loss and still unfavourable cash flow.
Exhibit 1: Medserv FY18 results summary
Year to December (€m) |
2017 |
2018 |
% change |
Revenues |
28.8 |
36.2 |
26% |
EBITDA adjusted, company definition |
4.3 |
7.3 |
69% |
EBITDA adjusted, Edison definition |
3.7 |
6.3 |
71% |
Operating profit (Edison adjusted) |
(1.2) |
(0.3) |
-75% |
Operating profit (reported) |
(4.1) |
(3.5) |
-15% |
Adjusted PBT |
(3.6) |
(3.4) |
-5% |
Adjusted EPS (c) |
(5.55) |
(6.76) |
22% |
Net debt |
49.2 |
53.7 |
9% |
Source: Medserv reports, Edison Investment Research
The ILSS segment contributed 61% of revenues with the OCTG operations of METS contributing the remainder, which compares to the even segment split in FY17. In terms of adjusted EBITDA, it was METS that made the difference, increasing its contribution by 87% to €5.8m (FY17: €3.1m). ILSS contributed €1.0m, a modest improvement on the €0.7m generated in the prior year.
In ILSS, despite and to a degree as a result of the continuing political uncertainty, a large part of the Malta base revenues result from servicing Libya’s offshore fields located 120km off the coast. Revenues from customers incorporated in Libya increased to €8.9m from €7.2m in the prior year. The Portugal contribution remained relatively stable, but the project has now ended and the focus shifted to Cyprus following the major field discoveries in 2018 and early 2019. Cyprus base revenues more than doubled to €5.8m (FY17: €2.4m). Egypt grew its contribution as the operations for ENI were mobilised in the existing bases, and in Q418 made a positive EBITDA, with FY18 revenues of €1.6m from a standing start. The photovoltaic farm at the Malta base continues to make a consistent contribution of around €0.5m to revenues with a strong EBITDA contribution.
|
Exhibit 2: Medserv revenue split by location FY18 (€36.2m) |
Exhibit 3: Medserv revenue split by segment FY18 (€36.2m) |
|
|
|
Source: Medserv reports |
Source: Medserv reports |
|
Exhibit 2: Medserv revenue split by location FY18 (€36.2m) |
|
|
Source: Medserv reports |
|
Exhibit 3: Medserv revenue split by segment FY18 (€36.2m) |
|
|
Source: Medserv reports |
For the OCTG operations of METS, revenues were broadly flat at €14.2m (FY17: €14.3m), which was below our expectations, largely due to deferrals of projects as well as the impact of transferring operations within Oman to the new facility at Duqm. Iraq again remained tough, but there are signs of improvement in Q119 figures.
Outlook
Even more encouraging are the outlook comments from management, which indicate a doubling of group revenues is expected for FY19, and is reflected in the newly released Financial Analysis Summary for FY19.
|
Exhibit 4: Medserv revenue development by location of operations |
|
|
Source: Medserv reports, Edison Investment Research estimates |
Clearly the major driver comes in ILSS (offshore base management and support) where the €30m 15-month contract for Suriname started to mobilise in January 2019. Drilling activity will likely increase as the year progresses and we expect around €25m of revenue to be booked for FY19. The uplift supports a healthy rise in group profitability, although we expect it to generate below FY18 group margin levels due to its nature as a management services contract. The contract is thus a new revenue stream as the company manages the base and services for the customer rather than using its own personnel, facilities and equipment. We expect Medserv to replicate this type of contract elsewhere in the world.
Apart from the success in Suriname, progress elsewhere also appears encouraging. For ILSS a successful initial drilling programme in Cyprus is increasing customer interest in the area, with ExxonMobil becoming a second customer for the Limasso base. Others are likely to enter the region following the discoveries, including to countries with adjacent block opportunities. The new Egypt base is also building activity levels and is in the process of consolidating activities from the customer’s former sites onto the new facility at Damietta. Egypt started to generate a positive EBITDA in Q4 so we would expect a significant progressive contribution to revenues and earnings as the Zohr field and other developments pick up pace. Again there is potential for additional work as other IOCs are showing interest to subcontract their shore base logistics. The Malta base is being kept busy by offshore Libya programmes, which in FY20 should include increased activity in support of the new offshore production structures being installed in the Bahr Essalam field.
For the OCTG business, METS FY18 was relatively flat with the largest contributor Oman continuing to make progress, but Iraq again remaining tough. Further growth is expected in Oman in the current year following the transfer to the new Duqm site.
FY19 should therefore be a year of expansion thanks largely to the success in Suriname, but other major growth opportunities exist for both ILSS and OCTG, which we have not included in our forecasts. Prospects include major OCTG projects in Uganda and a new territory in the Middle East, and Oman may provide the first cross-selling opportunity between the divisions with a possible offshore base for a customer being contemplated at Duqm.
We have revised our numbers in light of the newly released guidance for FY19 and the Q119 report. Our significantly increased new FY19 estimates remain slightly below the company’s FY19 forecast for €64.2m of revenues and adjusted EBITDA of €14.1m. Our revisions are summarised below:
Exhibit 5: Medserv earnings estimates revisions
Year to December (€m)
|
2018e |
2018 |
% change |
2019e |
2019e |
% change |
2020e |
Malta operation |
11.0 |
12.9 |
17.4% |
13.2 |
13.9 |
5.6% |
18.8 |
Libya |
0.5 |
0.0 |
-100.0% |
0.5 |
0.0 |
-100.0% |
0.0 |
Cyprus |
3.5 |
5.8 |
65.4% |
3.6 |
5.6 |
54.2% |
10.6 |
Portugal |
0.8 |
1.1 |
51.2% |
0.0 |
0.0 |
|
0.0 |
Egypt |
2.0 |
1.6 |
-18.1% |
2.2 |
3.3 |
48.9% |
5.9 |
Suriname |
|
|
|
|
25.0 |
|
5.0 |
METS |
17.7 |
14.2 |
-19.7% |
19.2 |
14.8 |
-23.1% |
16.4 |
Photovoltaic farm |
0.5 |
0.5 |
-5.0% |
0.5 |
0.5 |
-5.0% |
0.5 |
Revenues |
36.0 |
36.2 |
0.5% |
39.3 |
63.1 |
60.5% |
57.2 |
|
|
|
|
|
|
|
|
EBITDA adjusted (company definition) |
7.2 |
7.3 |
1.0% |
11.3 |
14.0 |
24.5% |
15.7 |
EBITDA adjusted (Edison definition)* |
6.5 |
6.3 |
-3.1% |
10.5 |
13.1 |
25.0% |
14.8 |
Depreciation |
(5.6) |
(7.9) |
40.5% |
(5.8) |
(8.6) |
48.2% |
(8.7) |
Other operating income |
|
1.3 |
|
|
0.9 |
|
0.9 |
Operating profit (adjusted) |
0.9 |
(0.3) |
N/A |
4.7 |
5.4 |
15.3% |
7.0 |
Exceptionals (incl. PPA amortisation) |
(1.6) |
(3.1) |
93.8% |
(1.5) |
(1.8) |
21.7% |
(1.8) |
Operating profit (reported) |
(0.7) |
(3.5) |
544.4% |
3.2 |
3.6 |
12.3% |
5.2 |
|
|
|
|
|
|
|
|
Profit before tax (adjusted) |
(3.0) |
(3.4) |
13.1% |
0.5 |
2.4 |
364.4% |
4.2 |
|
|
|
|
|
|
|
|
EPS - underlying continuing (c) |
(1.4) |
(6.8) |
383.0% |
4.7 |
5.2 |
11.5% |
8.9 |
DPS (c) |
2.0 |
0.0 |
N/A |
2.0 |
0.0 |
N/A |
2.0 |
Net debt |
54.6 |
53.7 |
-1.6% |
53.2 |
50.0 |
-6.1% |
43.2 |
Source: Medserv accounts, Edison Investment Research estimates. Note: *Excludes other operating income.
We expect a modest reduction in net debt in FY19 and positive adjusted EPS, but do not expect a dividend to be declared. We expect sufficient progress in FY20 for a resumption of payments.
Our new FY20 forecasts show that despite revenues declining on the assumption that Suriname ends and the major additional anticipated contracts do not get awarded, there will still be significant progress in FY20 company defined adjusted EBITDA of €15.7m and underlying EPS of €0.089.
Q119 trading reflects strengthening prospects
Q119 trading supports the view that the full year should see substantial progress.
Exhibit 2: Q119 trading summary
Three months to March (€m) |
Q118 |
Q119 |
% change |
|
■ ILSS |
4.9 |
9.0 |
84% |
|
■ OCTG |
3.3 |
3.4 |
3% |
|
■ PV farm |
0.1 |
0.1 |
0% |
Group revenues |
8.3 |
12.5 |
51% |
EBITDA adjusted (company definition) |
1.4 |
3.6 |
157% |
Margin |
16.9% |
28.8% |
Source: Medserv reports
As expected, the mobilisation in Suriname has led to a strong improvement of ILSS revenues during the first quarter, with OCTG making more modest progress. The overall increase of 51% has supported EBITDA (company definition) growth of 157% to €3.6m, which readily supports the company guidance for FY19. ILSS is likely to have been the main contributor, but with support coming from OCTG as a recovery in Iraqi performance is noted.
For OCTG, both an additional long-term contract in Uganda and a supply chain management contract in the Middle East are progressing towards award, with METS well positioned to win them. The additional supply chain management contract has the potential to be larger than the current one for Oman, while the Uganda contract would be smaller but a stable contributor.
ILSS also continues to pursue additional base opportunities in the Middle East (eg for offshore Oman) as well as adjacencies to its now established presence in Suriname, following the recent success in neighbouring Guyana by ExxonMobil. If Suriname does find oil it seems likely in our view that the contract end next year will have to be positively revised.
Valuation
Our capped DCF valuation currently returns a value of €1.33 per share. We use a calculated WACC of 8.1% and a terminal growth rate of zero, with working capital neutralised and depreciation normalised with capex. The sensitivity of our DCF to WACC and terminal growth rate assumptions is shown in the table below
Exhibit 7: Medserv capped DCF value per share (€) sensitivity to WACC and terminal growth
WACC |
6.0% |
7.0% |
8.0% |
8.1% |
9.0% |
10.0% |
15.0% |
Terminal growth rate |
|||||||
0% |
2.41 |
1.86 |
1.46 |
1.33 |
1.14 |
0.89 |
0.14 |
1% |
3.01 |
2.27 |
1.75 |
1.59 |
1.36 |
1.05 |
0.20 |
2% |
3.90 |
2.84 |
2.14 |
1.94 |
1.64 |
1.26 |
0.27 |
3% |
5.39 |
3.70 |
2.68 |
2.41 |
2.01 |
1.53 |
0.34 |
Source: Edison Investment research estimates
We note that we feel there are significant potential upside opportunities for earnings and cash flows from FY20 that we have yet to include in our assumptions. In its Q1 report, Medserv states that all subsidiaries have potential to increase earnings as a result of discoveries or new contract awards.
Exhibit 8: Financial summary
€m |
2017 |
2018 |
2019e |
2020e |
||
Year end 31 December |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
||||||
Revenue |
|
|
28.8 |
36.2 |
63.1 |
57.2 |
Cost of Sales |
(18.2) |
(23.6) |
(45.1) |
(37.2) |
||
Gross Profit |
10.6 |
12.6 |
18.0 |
20.0 |
||
EBITDA (Edison defined) |
|
|
3.7 |
6.3 |
13.1 |
14.8 |
Operating Profit (before amort. and except.) |
|
|
(1.2) |
(0.3) |
5.4 |
7.0 |
Intangible Amortisation |
0.0 |
0.0 |
0.0 |
0.0 |
||
Exceptionals |
(4.4) |
(5.4) |
(3.6) |
(3.7) |
||
Other |
0.8 |
1.3 |
0.9 |
0.9 |
||
Operating Profit |
(4.1) |
(3.5) |
3.6 |
5.2 |
||
Net Interest |
(3.9) |
(5.4) |
(4.8) |
(4.7) |
||
Profit Before Tax (norm) |
|
|
(3.6) |
(3.4) |
2.4 |
4.2 |
Profit Before Tax (FRS 3) |
|
|
(8.0) |
(8.8) |
(1.2) |
0.5 |
Tax |
0.4 |
(0.7) |
(0.1) |
0.0 |
||
Profit After Tax (norm) |
(3.2) |
(4.1) |
2.3 |
4.2 |
||
Profit After Tax (FRS 3) |
(7.6) |
(9.5) |
(1.3) |
0.5 |
||
Average Number of Shares Outstanding (m) |
53.7 |
53.7 |
53.7 |
53.7 |
||
EPS - normalised (c) |
|
|
(5.6) |
(6.8) |
5.2 |
8.9 |
EPS - normalised and fully diluted (c) |
|
|
(5.6) |
(6.8) |
5.2 |
8.9 |
EPS - (IFRS) (c) |
|
|
(13.8) |
(16.8) |
(1.5) |
2.0 |
Dividend per share (c) |
0.0 |
0.0 |
0.0 |
2.0 |
||
Gross Margin (%) |
36.8 |
34.8 |
28.5 |
35.0 |
||
EBITDA Margin (%) |
12.8 |
17.3 |
20.8 |
25.8 |
||
Operating Margin (before GW and except.) (%) |
-4.1 |
-0.9 |
8.5 |
12.2 |
||
BALANCE SHEET |
||||||
Fixed Assets |
|
|
46.4 |
46.4 |
44.6 |
42.4 |
Intangible Assets |
14.5 |
13.2 |
11.7 |
10.2 |
||
Tangible Assets |
31.9 |
33.2 |
32.9 |
32.2 |
||
Investments |
0.0 |
0.0 |
0.0 |
0.0 |
||
Current Assets |
|
|
106.9 |
110.4 |
112.6 |
108.6 |
Stocks |
1.2 |
1.3 |
1.7 |
1.6 |
||
Debtors |
12.2 |
12.8 |
16.8 |
15.2 |
||
Cash |
3.6 |
5.6 |
6.6 |
9.3 |
||
Other |
89.8 |
90.7 |
87.5 |
82.6 |
||
Current Liabilities |
|
|
(9.4) |
(16.2) |
(15.4) |
(13.9) |
Creditors |
(7.3) |
(10.9) |
(15.4) |
(13.9) |
||
Short term borrowings |
(2.0) |
(5.3) |
0.0 |
0.0 |
||
Long Term Liabilities |
|
|
(115.8) |
(121.9) |
(124.4) |
(120.3) |
Long term borrowings |
(50.8) |
(54.0) |
(56.6) |
(52.5) |
||
Other long term liabilities |
(65.0) |
(67.8) |
(67.8) |
(67.8) |
||
Net Assets |
|
|
28.1 |
18.7 |
17.4 |
16.8 |
CASH FLOW |
||||||
Operating Cash Flow |
|
|
1.8 |
6.6 |
10.9 |
13.2 |
Net Interest |
(2.4) |
(3.1) |
(3.0) |
(2.8) |
||
Tax |
0.4 |
(0.7) |
(0.1) |
0.0 |
||
Capex |
(2.6) |
(6.9) |
(4.1) |
(3.7) |
||
Acquisitions/disposals |
0.0 |
0.0 |
0.0 |
0.0 |
||
Financing |
0.6 |
(0.5) |
0.0 |
0.0 |
||
Dividends |
0.0 |
0.0 |
0.0 |
0.0 |
||
Net Cash Flow |
(2.3) |
(4.5) |
3.7 |
6.7 |
||
Opening net debt/(cash) |
|
|
47.0 |
49.2 |
53.7 |
50.0 |
HP finance leases initiated |
0.0 |
0.0 |
0.0 |
0.0 |
||
Other |
0.0 |
0.0 |
0.0 |
0.0 |
||
Closing net debt/(cash) |
|
|
49.2 |
53.7 |
50.0 |
43.2 |
Source: Company reports, Edison Investment Research estimates. Note: FY17 and FY18e P&L miscalculation in previous notes corrected here.
|
|
Research: Industrials
More good news from DATRON as confirmation of targeted growth in 2018 (revenue up 11% at enhanced like-for-like margin) has been accompanied by similarly positive guidance for the current year. Gains should continue to be investment-led, epitomised by the full-scale roll-out of the company’s ‘next’ tablet-based control system, driving demand in its key CNC milling machine segment, and by initial benefits from its specialist tool technology operation. Strong finances (c €10m net cash at end 2018) support investment (R&D 7% of 2018 sales) and dividend growth.
Get access to the very latest content matched to your personal investment style.
